CB-103

PreclinicalSmall molecule

CCellestia Biotech AG

CB-103 is one of 15 small molecule programs targeting Adenoid Cystic Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adenoid Cystic CarcinomaRecruiting

Adenoid Cystic CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

15 competitors in Adenoid Cystic Carcinoma

#DrugCompanyPhaseTrials

Adriamycin

Afinitor

Lenvima

5 4

Keytruda

Merck & Co.

Phase 2

2 5

Padcev

Pfizer

Phase 2

1 6

Rybrevant

Johnson & Johnson

Phase 2

1 7

Ellence

Pfizer

Phase 2

1 8

Zanzalintinib

Merck & Co.

Phase 2

1 9

Becotatug Vedotin

FFudan University

Phase 2

1 10

Verzenio

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Adenoid Cystic Carcinoma

NCT05774899

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumour1 trial

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Terminated·CCellestia Biotech AG·Phase 1/2·NCT03422679·79 enrolled

Breast Cancer1 trial

CB-103 Plus NSAI In Luminal Advanced Breast Cancer

Terminated·MMedSIR·Phase 2·NCT04714619·2 enrolled

Relapsed/Refractory1 trial

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT05464836·2 enrolled

Adenoid Cystic Carcinoma1 trial

A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)

Recruiting·GGlenn J. Hanna·Preclinical·NCT05774899·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CB-103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CB-103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CB-103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cellestia Biotech AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCellestia Biotech AG

CB-103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Advanced or Metastatic Solid Tumour1 trial

Breast Cancer1 trial

Relapsed/Refractory1 trial

Adenoid Cystic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News